Investigational drug · Phase 2
CIN-102 Dose
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Idiopathic Gastroparesis, Diabetic Gastroparesis.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
4
Any phase or sponsor naming "CIN-102 Dose"
First trial start
2023
Mar 27, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CIN-102 Dose", any sponsor or status.
Conditions studied
As listed on its trial records.
- Idiopathic Gastroparesis
- Diabetic Gastroparesis
Approved drugs for the same conditions: Cardiovascular and metabolic · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "CIN-102 Dose" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.Pivotal-lookingCompleted
CinDome Pharma, Inc.Industry
NCT06899217 · 416 participants · Start Jan 29, 2025 · Primary completion May 7, 2026
Drug: CIN-102 Dose 15mg; Placebo and 1 more · For: Idiopathic Gastroparesis
Sites: Birmingham, Alabama; Foley, Alabama; Saraland, Alabama · 85 sites in all
- A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic GastroparesisPivotal-lookingCompleted
CinDome Pharma, Inc.Industry
NCT05832151 · 382 participants · Start Mar 27, 2023 · Primary completion Nov 14, 2025
Drug: CIN-102 Dose 15mg or 10mg; Placebo · For: Diabetic Gastroparesis
Sites: Dothan, Alabama; Foley, Alabama; Huntsville, Alabama · 100 sites in all
CinDome Pharma, Inc.Industry
NCT04026997 · 72 participants · Start Sep 11, 2019 · Primary completion Dec 17, 2020
Drug: CIN-102 Dose 1; CIN-102 Dose 2 and 2 more · For: Gastroparesis
Sites: Chula Vista, California; Jacksonville, Florida; Miami, Florida · 19 sites in all
CinDome Pharma, Inc.Industry
NCT04208698 · 2 participants · Start Feb 17, 2020 · Primary completion Mar 31, 2020
Drug: CIN-102 Dose 1; CIN-102 Dose 2 and 1 more · For: Diabetic Gastroparesis
Sites: El Paso, Texas
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.